

Critical care “normality”: Individualized versus protocolized care

Julia Wendon, MB, ChB, FRCP

Patients with critical illness are heterogeneous, with differing physiologic requirements over time. Goal-directed therapy in the emergency room demonstrates that protocolized care could result in improved outcomes. Subsequent studies have confirmed benefit with such a “bundle-based approach” in the emergency room and in preoperative and postoperative scenarios. However, this cannot be necessarily extrapolated to the medium-term and long-term care pathway of the critically ill patient. It is likely that the development of mitochondrial dysfunction could result in goal-directed types of approaches being detrimental. Equally, arterial pressure aims are likely to be considerably different as the patient’s physiology moves toward “hibernation.” The agents we utilize as sedative and pressor agents have considerable effects on immune function and the inflammatory profile, and should be considered as part of the total clinical picture. The role of gut

failure in driving inflammation is considerable, and the drive to feed enterally, regardless of aspirate volume, may be detrimental in those with degrees of ileus, which is often a difficult diagnosis in the critically ill. The pathogenesis of liver dysfunction may be, at least in part, related to venous engorgement that will contribute toward portal hypertension and gut edema. This, in association with loss of the hepatosplanchnic buffer response, it is likely to contribute to venous pooling in the abdominal cavity, impaired venous return, and decreased central blood volumes. Therapies such as those used in “small-for-size syndrome” may have a role in the chronic stages of septic vascular failure. (Crit Care Med 2010; 38[Suppl.]:S590–S599)

KEY WORDS: gut failure; vasoactive agents; splanchnic blood flow; blood pressure; liver dysfunction; enteral feeding; immunoparesis; portal pressure; optimization; intestinal edema

Critical illness, regardless of its etiology, is a highly abnormal state in physiologic and physical terms. Our role as intensivists should be to provide a safe and supportive environment in which an individual patient’s homeostatic processes can return to health. There continues to be a tendency to assume that normalizing measured numbers and physiologic parameters will facilitate this process of recovery. Certainly, it makes the charts look “better.” However, the hard evidence for improved or faster recovery by undertaking such treatments is lacking. One of the issues pertaining to examining the literature is the manner in which research is undertaken and presented. The nature of a randomized controlled trial is to have a given hypothesis and to then choose a patient cohort with strict eligibility criteria. Many of the patients we, as clinicians, see coming through our care are often excluded. Furthermore, stan-

dards of care with the area of interest of the trial product often are not addressed. So, how should we treat patients who would have been excluded from such trials? More often than not, it seems that the desire to undertake something new and exciting wins and patients are offered the “new, better management.” The phenomenon of “product/protocol” creep is observed and outcomes of diverse groups then are not investigated effectively. Case series equally have a tendency to report only positive findings, and thus their suggested treatments should also be viewed with a degree of suspicion. Another potential issue is that the patient cohort in the critical care environment is far from homogeneous. Even within a variety of subgroups there is marked variability in the severity of organ failure, physiologic derangement, and precipitating factors. Furthermore, the disease, or at least its phenotype, changes. Thus, the optimal treatment regimen for an individual in the first 48 hrs of an acute insult is likely to differ greatly from that at 7, 14, and 21 days into a period of critical illness. Should a secondary episode of nosocomial sepsis in the critical care environment be treated in the same manner as in someone who has been on a general ward for the previous week or weeks, or as in someone presenting *de novo* to the emergency room? Antibiotic selection will ob-

viously need to vary, depending on the situation. Maybe other treatment protocols and hemodynamic aims to obtain optimal outcomes should vary, also. Can it be appropriate to suggest that a patient who presents with a fever, tachycardia, and mean arterial pressure of 60 mm Hg with a normal urine output and creatinine be treated in an identical manner as someone with a similar picture who is already 2 wks into critical care and in established renal failure? We have learned the lessons with respect to mechanical ventilation and that striving for normal levels of $Paco_2$ is potentially detrimental. Yet for a variety of other support methods and interventions, we remain addicted to making the charts and organ functions look “normal.” Are we treating our patients or ourselves?

Standards of Care and Protocols

At present, a main driver of quality and consistency in critical care practice, and medicine as a whole, is the development and subsequent application of standards of care, checklists, protocols, and integrated care pathways. Having parameters is useful in providing consistency of delivered care, especially in the initial stages of sepsis or acute illness, or in a patient undergoing a specific, clearly defined procedure. They allow staff, the pa-

From Kings College London, Kings Health Partners (Denmark Hill), Institute of Liver Studies, Kings College Hospital, London, UK.

The author has not disclosed any potential conflicts of interest.

For information regarding this article, E-mail: Julia.wendon@kcl.ac.uk

Copyright © 2010 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

DOI: 10.1097/CCM.0b013e3181f20227

tient, and their loved ones to be able to track an expected clinical course. They are, by definition, most applicable to a patient whose clinical course is within the “normal range” and who has a limited number of comorbidities (1). However, some patients are outside the defined group for which the pathway was designed. In these scenarios, a proscribed care pathway may result in mediocrity or impaired outcomes for that individual vs. the benefit achieved for the majority. A standard care pathway/protocol is ideal for many yet should not be viewed as “tablets of stone.” Instead, one should be able to say, “this applies to most patients but is it suitable in this particular setting, and if not, why not?” Let us encourage thought because surely this is how we innovate. Thinking outside the “black box” of “normal” should be encouraged and form as much a part of ongoing education as the ability to review and cite guidelines.

We should recognize that guidance is frequently developed from controlled trials that excluded patient groups and, also, may fail to be replicated in the future. Furthermore, in assessing guidelines, one should be aware of the evidence that resulted in their development and to consider that composition of multiple strands of guidance may or may not result in a sum benefit.

Treatment protocols should also attempt to recognize the presenting phenotype. We no longer try to make the patient suit the ventilator, having developed more elegance and understanding in this area. However, for managing inflammation and organ dysfunction, we still seem to insist that the patient has read and conforms to the textbooks! It is likely that an individual’s presenting phenotype, determined no doubt by a mixture of environment, genetic profile, and microRNA (2, 3), should result in a variety of possible treatment options. We recognize the detrimental effects of activation of the sympathetic nervous system in many organ systems and the potential detriment of tachycardia in respect to endothelial function (4). Similarly, in the critically ill individual, the role of adrenergic stress may be modulated by the individual phenotype or, in some situations, agents that modulate these effects may prove beneficial (5, 6). Recognition of individual response parameters should result in individualized as opposed to generic care. So, for some, beta-blockade or corticosteroids or epinephrine may provide benefit.

In another context, a pressor without alpha or beta activity, such as vasopressin, may be optimal. Recognition of these differences may enable improved outcomes and permit greater understanding of the observed variance in outcomes after similar insults. The development of point-of-care biomarkers to individualize care should be an achievable aspiration of critical care.

Another aspect of protocolized care and guidance that requires comment is the manner in which they are subsequently applied as assessment tools of the quality of delivered care. Health care systems are, quite appropriately, striving to optimize quality and cost-effectiveness. In health management terms, guidelines provide an ideal format with which to score clinical services; a guideline exists and, as such, percentage compliance with said guidance can be presented as a quality measure. It is essential that clinicians are actively involved in the design of the audit tools, allowing divergence and innovation to be applied in appropriate clinical scenarios without the hospital management presenting an intensive care unit as providing poor standards of care based on compliance with guidance alone. Similarly, we must ensure that our energies are not focused on gaming audit results but in educating clinicians in the physiologic building blocks of critical care and ensuring they are provided with appropriate analytical and applied skills. To illustrate these points, I review different systems and highlight a few examples of what I believe to be inadequacies and discrepancies in our current thought processes and management regimens.

Cardiovascular

Blood pressure, fluid balance, cardiac index, and, increasingly it seems, the central venous oxygen saturation are frequently at the forefront of daily management plans within the intensive care unit. The clarity of thought I used to have as a junior staff member with regard to these parameters has declined in parallel with years of practice and amassed experience.

The evidence for striving for a given blood pressure is fraught with difficulty. What is “normal”? Is “normal” that which an individual would have when healthy and walking around in the upright position or while asleep? Should we temper our target to that which is “acceptable” in the first 48 hrs of sepsis/acute insult vs.

that needed for a later state of established organ “failure/hibernation” or “incipient organ dysfunction/hibernation”? Again, the clinical context and course for the individual patient is paramount in this decision paradigm. The pendulum of expert opinion swings widely from pressure or flow being the optimal end point of resuscitation. However, rarely, if ever, do we define the exact points of clinical care being examined, even though most studies relate to *de novo* admissions as opposed to the “long stayer.” We must not lose sight of the optimal end point, namely, recovery/regeneration of organ function. Ironically, in the long-term patient this requires us to maintain particular attention to detail. It may be that the aims and objectives over a given time course are variable and disparate.

A target mean arterial pressure (MAP) may be achieved with judicious intravenous fluid administration and, thereafter, with various vasoactive agents. The evidence base for a given blood pressure for physiologic functionality has not been determined; many would aim for an initial MAP of 70 mm Hg, with increased levels being striven for in the context of cerebral insults and attempts to preserve renal function. However, the data are far from clear. Within the neurologic literature there is the concept of the Lund hypothesis (7, 8), whereas in acute liver failure lack of autoregulation to pressure frequently results in MAP and intracranial pressure increasing in parallel (9, 10).

Recent case series provide some insight, albeit in general terms, with regard to MAP and eventual outcome. In a cohort of 111 cases of septic shock, logistic regression analysis for 30-day mortality showed MAP and lactate on arrival were significantly associated with 30-day mortality (10). Receiver-operator curves were plotted and the highest area under the curve value (0.835) was found for MAP <65 mm Hg, suggesting this cut-off may be optimal. Many reviews and guidelines for the management of septic shock target values of MAP between 60 and 75 mm Hg. The rationale to keep pressures higher than 60 to 65 mm Hg is that this is the level for many organs in which autoregulation ceases and flow becomes pressure-dependent. However, one of the risks of setting a given blood pressure as a sole end point of therapy is the tendency to increase pressure in the face of an under-resuscitated circulation, leading to excessive constriction, poor end-organ perfusion, and impaired microcir-

culatory flow (11–13). Dubin et al (12) showed decreased capillary perfusion density with increasing MAP, albeit with considerable individual variation. The optimization of flow and pressure in the management paradigm remains uncomfortable as the assessment of optimal fluid loading before the institution of pressors and inotropes remains generally inadequate. Use of pressure measures alone are likely to result in some receiving fluid who are already fluid-replete, whereas others will receive vasoconstrictor agents who would benefit from further volume (14). Equally, it must be recognized that dynamic measures of volume responsiveness, such as stroke volume variation and pulse pressure variation, are not applicable in the setting of cardiac arrhythmias and significant respiratory efforts.

Dunser et al (15) also examined arterial blood pressure during early sepsis and the relationship with eventual outcome. Interestingly, the area under the receiver-operator curve for 28-day mortality was greatest for values of MAP <60 mm Hg and mean perfusion pressure (measured as MAP central venous pressure) <45 mm Hg. A MAP value <60 mm Hg increased the risk of death by 2.96 (95% confidence interval, 1.06–10.36), whereas the need for renal replacement therapy was best predicted by MAP values <75 mm Hg. Notably, in many studies and in clinical practice, even if the MAP target is set at 65 mm Hg, there is a tendency for “pressure creep,” with increasing doses being administered to drive the MAP higher. A fundamental question that needs to be addressed as we examine the psychology of the workplace, and particularly that of the critical care area, are the bedside drivers of resident and nursing staff in the end points they achieve as opposed to those suggested.

Care should ideally be tailored to an individual’s needs. This was demonstrated in the renal bed by Derudder et al (16), who showed that renal blood flow, as assessed by renal Doppler studies, was highly variable in response to changes in MAP achieved by infusion of norepinephrine. Optimal flow was achieved at varying blood pressure for different individuals. Bourgoin et al (17) similarly showed no benefit with regard to renal function when MAP was increased from 65 to 85 mm Hg. Of interest, in the neonatal intensive care literature, the concept of permissive hypotension is considered in

those with signs of good perfusion. Outcomes were similar to those with normotension, whereas worse outcomes were seen in those in whom hypotension was treated (18).

The aforementioned studies relate to the initial stages of management of sepsis and septic shock. It may be that at this stage the clinical scenario is that of jeopardized organ function as opposed to failure/hibernation (19, 20). Thus, the parameters one may wish to strive for in conditions of acute reversibility will differ from those required a few days later when there is, for example, established renal failure. Driving pressure through a renal vascular bed when the kidney has been oligoanuric for >48 hrs is unlikely to result in normalization of function. Would a management protocol addressing such parameters result in speedier recovery of function? There is a lack of appropriate trials addressing this. Given the concern that inappropriate vasoconstriction may be detrimental, MAP values of 60 to 65 mm Hg may be adequate if there is adequate perfusion and end-organ function is stable. It has been suggested that continuous renal replacement therapy may favor renal recovery over intermittent continuous renal replacement therapy. However, studies by Palevsky and Vinsonneau (21–23) suggest that 60-day outcome is the same. In both studies the incidence of hypotension was 30% to 39% (defined as systolic blood pressure <80 mm Hg), yet renal recovery was seen in >90% of patients regardless of the mode of continuous renal replacement therapy applied. This may suggest that hypotension, although not persistent, does not impair renal recovery and that the assumed safer mode (continuous renal replacement therapy) in fact had as many complications as, if not more than, intermittent continuous renal replacement therapy. Another compounding issue associated with many of the forms of continuous renal replacement therapy in patients with sepsis is the lack of definitive data regarding appropriate dosing of antibiotics and antifungals, especially in the context of high volumes of distribution (24, 25).

Determination of adequate perfusion (both at whole body and organ levels) is problematic as the patient progresses from insult and precarious organ function to established organ dysfunction/hibernation. Several groups utilizing *in vitro* microscopy have elegantly examined the microcirculation (particularly

sublingual) and observed pathologic responses to certain constrictor therapies (26). Regarding whether these findings relate to endothelium activation and inflammation, the effects of constrictor therapy or to altered flow based on changing cellular requirements in the face of mitochondrial dysfunction is yet to be elucidated, as is the relationship to outcome.

It is also difficult to accurately predict how microcirculatory flow and oxygenation respond to vasoconstrictors and dilators (11, 27). For example, no difference in microcirculatory flow parameters was seen with or without nitroglycerine when a strict resuscitation protocol was utilized (28). Importantly, pressors are likely to have different effects on different organ beds; for example, the gut may be particularly sensitive to vasoconstrictor agents (29, 30). “Aggressive” control of blood pressure with constrictors after appropriate fluid loading may be optimal in the short-term but could prove detrimental over the medium term and longer term in a manner similar to what we now recognize for fluids. A fine balance exists between too much and too little. Perhaps we should utilize more sophisticated techniques, e.g., assessing tissue oxygen content and microcirculatory flow (26), although we should not lose sight of old-fashioned clinical skills such as detecting “warm edges” on the patient.

The type of vasoactive agent should also be considered. Vasopressin, norepinephrine, and epinephrine are, at present, the most commonly administered pressor agents. However, other approaches should not be discounted, even nitric oxide synthase blockade. Perusal of the major clinical trial investigating nitric oxide synthase blockade in septic shock suggests that, maybe, the “baby was thrown out with the bath water” (31), because many of the negative effects could have been the result of overzealous vasoconstriction. The data on vasopressin use are also unclear with regard to outcome benefit, although it would seem a useful adjunct to improve responsiveness to pressor agents, providing excessive doses are not administered (32–34). The risks of overconstriction and end-organ hypoperfusion holds with every agent, but perhaps especially in those with isolated pressor activity.

The finding of a relationship between mean perfusion pressure and 28-day outcome (15) is physiologically intuitive given that organ perfusion is determined

by the pressure gradient across any given organ. However, it is rare in modern intensive care unit practice to consider this variable except in the context of abdominal hypertension and abdominal compartment syndrome, in which intra-abdominal pressure may be considered a vital factor affecting renal and gut perfusion (35). Perhaps these physiologic relationships, in association with central venous pressure, should be evaluated in more detail to consider transmural pressure gradients. The finding of an elevated central venous pressure and a low perfusing pressure (mean or, more importantly, diastolic pressure) will significantly impact on coronary perfusion and, hence, cardiac performance. Especially in the face of a tachycardia and/or pulmonary hypertension and right heart dysfunction, this can result in inadequate substrate delivery to the cardiomyocyte. Early work by Cunio et al (20) showed equivalent coronary blood flow but no myocardial lactate production in those with and without cardiac dysfunction, raising the possibility of loss of autoregulation, disordered microcirculatory flow, and/or mitochondrial dysfunction. Investigators have demonstrated increased coronary sinus blood flow, particularly in those who failed to survive, with evidence of decreased stroke volume and ejection fraction despite elevated cardiac indices. Substrate utilization was altered with decreased fatty acid utilization and increased lactate consumption (36–38). We see little evidence of overt myocardial ischemia in the critically ill patient; however, elevated troponin levels are not uncommon. This could be, perhaps, viewed as a biomarker of myocyte stress, particularly in the early phases of sepsis and initial therapy, marking patients at higher risk for mortality, albeit acknowledging that renal clearance is a confounder (39–41).

Measuring and correcting central venous saturation (ScvO₂) now features strongly in sepsis guidelines (42, 43). The finding of a low value certainly warrants investigation and may be multifactorial; alterations in hemoglobin, oxygenation, and cardiac output should be considered, as should potential artifacts such as an erroneous catheter tip position. Equally, the finding of an elevated ScvO₂ should not be taken as explicit that the patient is volume-replete, especially in the setting of hyperdynamic states and microcirculatory failure. A recent study (44) examining initial management of sepsis in the

emergency department used protocols that included a central venous pressure >8 mm Hg; however, reported levels were between 11 and 16 mm Hg at 0, 24, 48, and 72 hrs after study entry.

Immune Status

The immune effects of the agents we administer equally should not be ignored (45–47). Epinephrine, as an example, has significant effects on leukocyte mobilization and demargination (48), whereas catecholamines in general induce an inflammatory response in hepatocytes (49). This may be physiologically beneficial in the early stages of sepsis, facilitating protection from invading pathogens; however, in the later stages of disease progression, they may be highly detrimental. Persistent stimulation with catecholamines (exogenous and/or endogenous) and circulating cytokines may contribute to transformation of monocytes to an endotoxin-tolerant, anti-inflammatory phenotype that may have implications in patients requiring prolonged critical care (50–52). Neutrophil function is also abnormal with disparity between opsonization and respiratory burst, and this also varies over time (53–56). Other agents commonly used in the critically ill also have significant effects on immune function. Etomidate is known to decrease adrenal function, whereas agents such as ketamine may be potentially beneficial through modulating the nitric oxide, carbon monoxide, and hydrogen oxide pathways (57–59). After endotoxin administration to rats, ketamine resulted in hepatic protection mediated, at least in part, through heme oxygenase-1 and carbon monoxide (59).

The clinical tendency to date has been an attempt to manipulate patients toward immunologic normality, with early dampening followed, potentially, by subsequent stimulation. Is either of these endeavors appropriate? If the hypothesis of “hibernation” is a clinical reality at certain time points during the clinical course, then being in a state of relative anergy could even be beneficial. Thus, immunostimulatory interventions may potentially prove detrimental. Many of our trial interventions in sepsis have been excessive and have also failed to impact positively on outcomes, e.g., (60, 61). In alcoholic hepatitis, the use of a tumor necrosis factor monoclonal antibody in combination with steroids resulted in increased mortality, even though studies

using tumor necrosis factor monoclonal antibody alone did not show harm (62, 63). Equally, in the animal literature, stimulatory agents such as granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor did not inevitably result in improved outcomes, albeit in patients there are some data suggesting decreased duration of mechanical ventilation and intensive care unit stay (64–66).

Finally, we should recognize that our decisions are based on levels of circulating cells and not those causing effects at sites of inflammation. This may be highly pertinent because some of the so-called states of functional immunoparesis we encounter may actually represent an effect of inflammation and resolution of inflammation at the primary site. As such, peripheral stimulation of immune functionality may have the potential to worsen organ function and delay healing (67, 68).

Renal, Intra-Abdominal Pressure, and Fluids

Perfusion pressure within the abdominal cavity may impact significantly on organ function. For example, pressure in the renal vein is similar to that in the abdominal cavity. Work in patients with cirrhosis has shown that, in the presence of ascites, renal vein pressure is frequently ≥ 20 mm Hg (69). However, drainage of large volumes of ascites has been associated with increased markers of renal dysfunction and sympathetic nervous system activation. The rationale probably relates to the marked reduction in intra-abdominal pressure being associated initially with improved venous return and cardiovascular stability, followed, over time, by splanchnic vasodilation, venous pooling, and, hence, volume depletion (70). These effects can be countered with appropriate volume loading or maintaining a given intra-abdominal pressure, possibly by administering a splanchnic vasoconstrictor. Similar physiologic changes are also likely to be seen in a critically ill patient. This may be of particular concern given that fluid therapy may be detrimental in intra-abdominal hypertension, hence propagating the tendency to overconstrict to achieve a given MAP or abdominal perfusion pressure. That high intra-abdominal pressure (>25–30 mm Hg) is detrimental is clearly established (71–74). There is, however, less clarity regarding the opti-

mal management of increased pressures below these levels. Ascitic drainage easily can be undertaken under ultrasound guidance and ileus diminished with nasogastric drainage. Whether decompressive laparostomy is appropriate in the context of a nonsurgical abdomen is considerably less clear. In those in whom laparostomy is undertaken, consideration should be given to the fluid and nitrogen losses that can occur (75).

Renal outcome has been examined with regard to MAP in several studies. Again, optimal renal perfusion pressure has yet to be established, but it is unlikely that therapeutic manipulations will have an effect on anything other than the acute stages of the renal insult. So, at what time point is it acceptable to drive the target mean arterial pressure to, for example, 75 mm Hg? Perhaps only for the first 48 hrs of presentation or oliguria would seem logical. Oliguria seems to prompt clinicians to reach for fluids and pressor agents, but it should perhaps be viewed with a degree of equanimity. Initially, it should be viewed as a “red flag” to ensure there is no reversible cause. If the oliguria persists, then instead of pouring in fluids—of dubious quality and effect—or potentially excessively vasoconstricting with pressor agents, oliguria could be viewed as an appropriate physiologic response to an insult. The desire to generate urine, regardless of quality, is then normally addressed through the liberal administration of diuretics. Even in those relatively rare cases in which a response is seen, the quality is usually poor and the metabolic side effects, which are significant, are largely ignored. A major failing is the tendency to provide inadequate hydration with crystalloid solutions while avoiding the detrimental effects of hyperchloremia (76). The excessive administration of colloid has rightly received poor press, with several studies showing that both starch and gelatin solutions are associated with increased rates of acute renal injury (77–79), and that a positive fluid balance is associated with increased mortality (80, 81). However, the large, blinded, multicenter study of Finfer et al (82) showed overall no difference between groups randomized to crystalloid or 4.5% human albumin solution. Nevertheless, subgroup analysis did suggest a potential benefit of albumin in the sepsis group but harm in patients after trauma, particularly head injury. Hepatology studies (83–86) attest to the beneficial effects of albumin, albeit

20% solutions, in both bacterial peritonitis and hepatorenal failure. However, the SOAP study found that albumin therapy was associated with increased mortality (87). Perhaps the role of albumin should be addressed as a potential drug rather than as a simple fluid. It is an antioxidant and a binder of various vasoactive substances (88, 89); the hemodynamic benefits observed during molecular adsorbents recirculation system treatment may, at least in part, be attributable to “cleansing” of native circulating albumin and thus improving its binding capacity (90). Importantly, all commercial albumin solutions contain preservatives. A study examining stimulation of peripheral monocytes in the presence of albumin solutions with and without the presence of preservatives suggests that, at least *in vitro*, the preservative-treated albumin has anti-inflammatory properties (91). Thus, in the setting of an acute systemic inflammatory response and a hyperactive immune response, it could be postulated that infused albumin may act as both a volume expander and an anti-inflammatory agent and have potential benefit. By contrast, infusion of albumin later in the clinical course when the immune status is anti-inflammatory may be detrimental to outcome.

Goal-Directed Therapy, Lactate, and Glucose

The role of protocolized care may be suitable for the initial stages of sepsis (43, 92); however, its benefits may be more dubious and potentially even detrimental in patients with established organ dysfunction. The original work of Rivers et al (93) has been repeated in different contexts and does appear to be beneficial in the emergency department setting (94). Contextually, this is logical and similar to the “golden hour” of trauma, *i.e.*, early flow-driven resuscitation is beneficial. In many aspects the care pathway is similar to that of the preoperative and perioperative surgical patient at high risk in whom optimization of fluid status and flow improved outcomes with decreased morbidity and shortened length of stay (95–98).

It should be noted that the care bundles and protocols recommended for managing sepsis utilize many of the support systems that are now being questioned, such as steroids for vasopressor dependence (99). By contrast, protocolized optimization of the patient with es-

tablished critical illness (addressing oxygen delivery, uptake, and cardiac indices) has failed to improve outcome and may actually increase mortality (100). Caution thus should be addressed in extrapolating data from one clearly defined clinical context to the whole management process of the critically ill patient with established organ failure/dysfunction. Targets of ScvO₂ and central venous pressure are contentious end points for resuscitation in this context. Venous pressure needs to be addressed as a dynamic response variable with intra-abdominal pressure taken into account. ScvO₂ is likely to be influenced by the high-output states that are often the standard in established organ failure. In this case, a high ScvO₂ may not be reflective of adequate volume status but more a reflection of cellular dysfunction and limited oxygen uptake—cytopathic dysoxia. Studies demonstrate that high and low ScvO₂ levels are associated with poor outcome (101). Recent work has also suggested that lactate is a powerful prognosticator in patients with sepsis independent of organ failure and shock (102). Clarity in regard to what is optimal remains elusive, so one of the great potential benefits for adopting protocols, at least in the short term to medium term, may be attention to detail with improved outcomes in a manner similar to that observed when enrolled into a clinical trial.

The elevated ScvO₂ seen in many patients with organ failure and critical illness may be driven by the hyperdynamic state with shunting through the microcirculation and/or cellular dysoxia. Previously, a high ScvO₂ and low oxygen extraction ratio were thought to represent inadequate nutritive flow. The assumption that increasing oxygen uptake would result in improved outcome resulted in a series of studies driving cardiac output with pressors and inotropes; such studies resulted in increased mortality (100) or no benefit (103). Elevated lactate levels were also thought to be the result of tissue hypoxia, although various studies have now demonstrated that this is largely a result of aerobic glycolysis and increased Na⁺/K⁺ATPase activity in skeletal muscle (104–106) with normal tissue oxygen levels. This should not suggest that lactate is not a useful biomarker; it remains a strong prognostic marker and represents a balance between cellular production driven by aerobic glycolysis and the capacity of organs, particularly the liver, to metabolize the available lac-

tate. It is frequently responsive to fluid loading, at least at initial presentation. The finding of normal tissue oxygen levels has resulted in the suggestion that much of the organ dysfunction in critical illness is related to mitochondrial dysfunction, although not all the literature supports this view (20, 107–109). Mitochondrial function is reported in various articles to be unchanged or decreased, with decreased activity being seen more frequently in established sepsis (110). Furthermore, this dysfunction is reversible and offers the opportunity for novel therapeutic intervention (108, 111–113).

Tight blood glucose control has been shown in some studies to be either beneficial or harmful, especially in relation to hypoglycemia (77, 114–116). Of interest, however, were the findings from the initial study of Van de Berghe et al (117) that postmortem liver biopsy results of those receiving tight blood glucose control showed significantly less mitochondrial ultrastructural damage and disruption with preserved mitochondrial respiratory chain complex I. These conflicting data should not prevent clinical care striving for reasonable levels of glucose while avoiding low levels.

Liver and Gastrointestinal Function

Liver dysfunction in sepsis is multifactorial in nature (118) but is most prevalent in Gram-negative and intra-abdominal sepsis (119, 120). It is also more likely to be seen in those with abnormal underlying liver function. The observed hyperbilirubinemia is the most easily recognized marker of liver dysfunction, but this does not normally present until some days after the initial insult. Any intervention designed solely to decrease bilirubin is, however, unlikely to be fruitful; bilirubin is a marker of dysfunction rather than an etiological factor.

The splanchnic bed is a large vascular bed with a potentially significant role to play in the cardiovascular and gut failure of sepsis/inflammation. After initial vasodilatation and central volume depletion, there is activation of the sympathetic and renin-angiotensin-aldosterone systems. The vascular supply to the liver is from the hepatic artery and portal vein. Blood flows through a sinusoidal bed, passing down an oxygen gradient from zone one to three. Venous drainage is *via* the hepatic veins directly into the inferior vena cava and back to the right atrium. Thus,

elevated right atrial pressures are likely to result in liver congestion and may also elevate portal pressures. Resistance then increases in the organs draining into the portal venous system—the intestine, stomach, and spleen. Significant increases in right atrial pressure will also result in exudative interstitial edema, with a potential cycle of impaired hepatic venular flow, endothelial inflammation, increased intrahepatic resistance, and, in the longer-term, fibrosis. As portal pressure increases, bowel edema will develop; as portal pressure increases to >12 mm Hg, there is the potential for varices to develop with portosystemic shunting. This allows delivery of endotoxin and bacterial toxins from the gut to enter the systemic circulation with further inflammation and increased risk of further liver involvement.

One of the vascular hypotheses of liver injury promoted by Wanless (121–123) is aligned with the observation of parenchymal extinction and collapse associated with hepatic venous outflow occlusion and is potentially equally applicable to the liver injury seen in sepsis and inflammation. It may be that some of the hyperbilirubinemia observed in the sepsis literature pertains to aberrant vascular flow and parenchymal obliteration in addition to the recognized and more greatly studied changes in hepatocyte transporters and bile flow (124). Animal studies support these hypotheses (125–127). End points of resuscitation should consider the relationship between right atrial and portal pressure; dynamic assessment of liver function should be considered as a potentially important end point. The liver is, especially in this milieu, a highly metabolically active organ, being an intrinsic part of the fixed reticulo-endothelial system and contributing to cytokine production, acute phase response, and drug metabolism, among others. As such, appropriate delivery of both nutritive flow and adequate venous drainage should be viewed as an essential component of management of the critically ill patient. Thus, thoracic but not lumbar epidural anesthesia results in increased indocyanine green clearance after major abdominal surgery (128). Increased intrahepatic resistance plus an increased splanchnic inflow have the potential to result in a pattern of disease similar to that seen after liver resection and living related transplantation, *i.e.*, small-for-size syndrome (129–131). This model may offer alternative treatments for hepatic dys-

function of sepsis, ensuring that portal inflow does not become excessive as liver resistance increases, and considering modulatory agents such as beta-blockers, vasopressin/terlipressin, and other agents that decrease intrahepatic resistance.

The balance between intestinal ischemia and avoidance of splanchnic hyperemia is likely a fine balance. The monitoring tools available at the present time do not readily address these issues. One could perhaps reconsider the use of tonometry when an increase in gastric end-tidal (or gastric arterial) CO₂ gap was classically considered representative of intestinal ischemia, and when those patients whose gap was either normal or resolved with resuscitation were found to have improved outcome (30, 132). One could hypothesize that an elevated CO₂ gap may be representative of impaired venous return, as could be seen in portal hypertension and increased liver resistance. Tonometry in patients recovering from acute liver failure was initially normal and then deteriorated during their period of recovery in a time frame that was associated with the development of portal hypertension (133).

Is it appropriate to insist on early enteral nutrition in all patients in the critically ill environment? Again, a one-size-fits-all checklist approach is likely to benefit perhaps the majority but risks significant detriment to a minority. Certainly, data on early postoperative nutrition appear beneficial. Delivery of food to the gastrointestinal tract will result in increased blood flow to the intestine via the superior mesenteric artery (134). In health, splanchnic flow will remain constant by virtue of the hepatic buffer response; however, in sepsis, this response is impaired (135), with the potential to result in splanchnic pooling and central volume depletion. This, in turn, will result in increased venous drainage through the portal vein and, in a situation of elevated pressures or increased intrahepatic resistance, there will be further venous engorgement with development of spontaneous porto-mesenteric shunts and mucosal edema. In patients with large nasogastric aspirates, gastric emptying is promoted with prokinetics (none of which are without potential side effects), and when it fails a nasojejunal tube may be inserted. In some patients food continues to be delivered to an immobile, poorly functioning gut, and this may result in ileus with periods of sepsis and inflammation from the dilated,

edematous intestine. Normal functioning of a gastrointestinal tract is an excellent prognostic sign, but the extrapolation of forcing the gut to work to achieve an improved outcome is not clear and may be detrimental. In experimental models of superior mesenteric venous ligation, gut edema *per se* has been shown to benefit from feeding (136). However, this may not be replicated in clinical scenarios with the compounding effects of liver resistance and systemic inflammation. People do not wish to imbibe food in large volumes when they have a fever or are otherwise unwell. Although starvation is not an option in the long term, it is likely that early and aggressive enteral nutrition is potentially harmful in some patients, and certainly in those in receipt of high-dose vasopressors (137). A recent study (138) examining enteral feeding with or without probiotics in severe necrotizing pancreatitis and the findings of ischemic bowel should be viewed with concern. It may not so much be the effects of the probiotics that were being observed in this scenario but the effects of enteral feeding in unstable patients with organ failure (139). The effect of enteral feeding on intestinal function also may be related to the timing of feeding in respect to the subsequent insult. Importantly, total parenteral nutrition (TPN), instituted before ischemia, resulted in worsened vascular permeability in distant organs compared with enteral feeding (140). By contrast, involuntary feeding instituted after ischemia reperfusion injury showed worse outcomes (141). Thus, in the context of shock and severe ischemia reperfusion injury, early feeding may be best avoided, at least in the early stages of treatment.

The poor reputation of parenteral feeding dates back many years and is classically associated with villous atrophy, cholestasis, and sepsis. Recent studies from Spain showed that early institution of artificial nutrition appeared protective. However, in multivariate analysis, TPN, sepsis, and excessive calculated energy requirements were risk factors for liver dysfunction (142, 143). It may be that in those with an early liver insult, not yet associated with measured derangement in liver biochemistry, there would be an increase in transhepatic resistance with decreased sinusoidal flow secondary to white cell adherence and sinusoidal endothelial constriction, and subsequent elevation of portal pressure. This cohort will likely demonstrate early intolerance

of enteral nutrition and early TPN should be considered. The causal relationship between liver dysfunction and TPN is not clear. The finding of liver dysfunction in the enterally fed group was still significant at 18%, but it was lower than the 30% incidence observed in those who received TPN. Perhaps the latter group had a higher incidence of gut failure and, in some cases, this may have been attributable to early liver dysfunction as delineated. The splanchnic bed remains, in clinical terms at least, something of a "black box." Predictors of gut failure are lacking and indocyanine green clearance has only been taken-up by a small number of enthusiasts. The reluctance to institute TPN should be reassessed and potentially addressed sooner in those who show signs of gastrointestinal intolerance. The risks of TPN-associated liver dysfunction can be significantly decreased by avoidance of overfeeding, appropriate carbohydrate-to-fat ratio, attention to blood glucose control, and scrupulous line care.

REFERENCES

1. Kavanagh BP, Meyer LJ: Normalizing physiological variables in acute illness: five reasons for caution. *Intensive Care Med* 2005; 31:1161–1167
2. Fredriksson K, Tjader I, Keller P, et al: Dysregulation of mitochondrial dynamics and the muscle transcriptome in ICU patients suffering from sepsis induced multiple organ failure. *PLoS One* 2008; 3:e3686
3. Yang BF, Lu YJ, Wang ZG: MicroRNAs and apoptosis: Implications in the molecular therapy of human disease. *Clin Exp Pharmacol Physiol* 2009; 36:951–960
4. Thorin E, Thorin-Trescases N: Vascular endothelial ageing, heartbeat after heartbeat. *Cardiovasc Res* 2009; 84:24–32
5. Dunser MW, Hasibeder WR: Sympathetic overstimulation during critical illness: Adverse effects of adrenergic stress. *J Intensive Care Med* 2009; 24:293–316
6. Schmittinger CA, Dunser MW, Haller M, et al: Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. *Crit Care* 2008; 12:R99
7. Czosnyka M, Brady K, Reinhard M, et al: Monitoring of cerebrovascular autoregulation: facts, myths, and missing links. *Neurocrit Care* 2009; 10:373–386
8. Nordstrom CH, Reinstrup P, Xu W, et al: Assessment of the lower limit for cerebral perfusion pressure in severe head injuries by bedside monitoring of regional energy metabolism. *Anesthesiology* 2003; 98: 809–814
9. Dethloff TJ, Knudsen GM, Larsen FS: Cerebral blood flow autoregulation in experi-

- mental liver failure. *J Cereb Blood Flow Metab* 2008; 28:916–926
10. Varpula M, Tallgren M, Saukkonen K, et al: Hemodynamic variables related to outcome in septic shock. *Intensive Care Med* 2005; 31:1066–1071
11. Maier S, Hasibeder WR, Hengl C, et al: Effects of phenylephrine on the sublingual microcirculation during cardiopulmonary bypass. *Br J Anaesth* 2009; 102:485–491
12. Dubin A, Pozo MO, Casabella CA, et al: Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: A prospective study. *Crit Care* 2009; 13:R92
13. Dunser MW, Ruokonen E, Pettila V, et al: Association of arterial blood pressure and vasopressor load with septic shock mortality: A post hoc analysis of a multicenter trial. *Crit Care* 2009; 13:R181
14. Osman D, Ridet C, Ray P, et al: Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge. *Crit Care Med* 2007; 35:64–68
15. Dunser MW, Takala J, Ulmer H, et al: Arterial blood pressure during early sepsis and outcome. *Intensive Care Med* 2009; 35: 1225–1233
16. Deruddre S, Cheisson G, Mazoit JX, et al: Renal arterial resistance in septic shock: effects of increasing mean arterial pressure with norepinephrine on the renal resistive index assessed with Doppler ultrasonography. *Intensive Care Med* 2007; 33: 1557–1562
17. Bourgoin A, Leone M, Delmas A, et al: Increasing mean arterial pressure in patients with septic shock: Effects on oxygen variables and renal function. *Crit Care Med* 2005; 33:780–786
18. Dempsey EM, Al Hazzani F, Barrington KJ: Permissive hypotension in the extremely low birthweight infant with signs of good perfusion. *Arch Dis Child Fetal Neonatal Ed* 2009; 94:F241–F244
19. Mongardon N, Dyson A, Singer M: Is MOF an outcome parameter or a transient, adaptive state in critical illness? *Curr Opin Crit Care* 2009; 15:431–436
20. Levy RJ: Mitochondrial dysfunction, bioenergetic impairment, and metabolic down-regulation in sepsis. *Shock* 2007; 28:24–28
21. Palevsky PM, O'Connor TZ, Chertow GM, et al: Intensity of renal replacement therapy in acute kidney injury: Perspective from within the Acute Renal Failure Trial Network Study. *Crit Care* 2009; 13:310
22. Palevsky PM, Zhang JH, O'Connor TZ, et al: Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med* 2008; 359:7–20
23. Vinsonneau C, Camus C, Combes A, et al: Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: A multicentre randomised trial. *Lancet* 2006; 368: 379–385

24. Roberts JA, Kirkpatrick CM, Roberts MS, et al: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. *J Antimicrob Chemother* 2009; 64:142–150
25. Li AM, Gomersall CD, Choi G, et al: A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: Do current studies supply sufficient data? *J Antimicrob Chemother* 2009; 64:929–937
26. Arnold RC, Parrillo JE, Phillip Dellinger R, et al: Point-of-care assessment of microvascular blood flow in critically ill patients. *Intensive Care Med* 2009; 35:1761–1766
27. Trzeciak S, Dellinger RP, Parrillo JE, et al: Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: Relationship to hemodynamics, oxygen transport, and survival. *Ann Emerg Med* 2007; 49:88–98, 98e81–98e82
28. Boerma EC, Koopmans M, Konijn A, et al: Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: A double-blind randomized placebo controlled trial. *Crit Care Med* 2010; 38:93–100
29. Maier S, Hasibeder W, Pajk W, et al: Arginine-vasopressin attenuates beneficial norepinephrine effect on jejunal mucosal tissue oxygenation during endotoxaemia. *Br J Anaesth* 2009; 103:691–700
30. Nygren A, Thoren A, Ricksten SE: Vasopressin decreases intestinal mucosal perfusion: A clinical study on cardiac surgery patients in vasodilatory shock. *Acta Anaesthesiol Scand* 2009; 53:581–588
31. Lopez A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. *Crit Care Med* 2004; 32:21–30
32. Simon F, Giudici R, Scheuerle A, et al: Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: A randomized controlled trial. *Crit Care* 2009; 13:R113
33. Kienbaum P, Prante C, Lehmann N, et al: Alterations in forearm vascular reactivity in patients with septic shock. *Anaesthesia* 2008; 63:121–128
34. Russell JA, Walley KR, Singer J, et al: Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008; 358:877–887
35. Cheatham ML, Malbrain ML, Kirkpatrick A, et al: Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome II. Recommendations. *Intensive Care Med* 2007; 33:951–962
36. Cunnion RE, Schaer GL, Parker MM, et al: The coronary circulation in human septic shock. *Circulation* 1986; 73:637–644
37. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al: Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. *Circulation* 1987; 75:533–541
38. McDonough KH, Lang CH, Spitzer JJ: Depressed function of isolated hearts from hyperdynamic septic rats. *Circ Shock* 1984; 12:241–251
39. Ammann P, Maggiorini M, Bertel O, et al: Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. *J Am Coll Cardiol* 2003; 41:2004–2009
40. Giannitsis E, Katus HA: Troponins and high-sensitivity troponins as markers of necrosis in CAD and heart failure. *Herz* 2009; 34:600–606
41. Lazzeri C, Bonizzoli M, Cianchi G, et al: Troponin I in the intensive care unit setting: From the heart to the heart. *Intern Emerg Med* 2008; 3:9–16
42. Levy MM, Dellinger RP, Townsend SR, et al: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. *Intensive Care Med*; 36:222–231
43. Ferrer R, Artigas A, Levy MM, et al: Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. *JAMA* 2008; 299:2294–2303
44. Jones AE, Shapiro NI, Trzeciak S, et al: Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: A randomized clinical trial. *JAMA* 2010;303:739–746
45. Javan B, Kao YH, Goto S, et al: Propofol pretreatment attenuates LPS-induced granulocyte-macrophage colony-stimulating factor production in cultured hepatocytes by suppressing MAPK/ERK activity and NF-kappaB translocation. *Toxicol Appl Pharmacol* 2008; 229:362–373
46. Spight D, Trapnell B, Zhao B, et al: Granulocyte-macrophage-colony-stimulating factor-dependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice. *Shock* 2008; 30:434–442
47. Toda H, Murata A, Oka Y, et al: Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. *Blood* 1994; 83:2893–2898
48. Dimitrov S, Lange T, Born J: Selective mobilization of cytotoxic leukocytes by epinephrine. *J Immunol* 2009; 184:503–511
49. Aninat C, Seguin P, Descheemaeker PN, et al: Catecholamines induce an inflammatory response in human hepatocytes. *Crit Care Med* 2008; 36:848–854
50. del Rey A, Randolf A, Wildmann J, et al: Re-exposure to endotoxin induces differential cytokine gene expression in the rat hypothalamus and spleen. *Brain Behav Immun* 2009; 23:776–783
51. Berczi I: Neurohormonal host defense in endotoxin shock. *Ann N Y Acad Sci* 1998; 840:787–802
52. West MA, Heagy W: Endotoxin tolerance: A review. *Crit Care Med* 2002; 30:S64–S73
53. Yoza BK, Hu JY, Cousart SL, et al: Induction of RelB participates in endotoxin tolerance. *J Immunol* 2006; 177:4080–4085
54. Reddy RC, Standiford TJ: Effects of sepsis on neutrophil chemotaxis. *Curr Opin Hematol* 2010; 17:18–24
55. Danikas DD, Karakantza M, Theodorou GL, et al: Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis Correlation to CD64 and CD14 antigen expression. *Clin Exp Immunol* 2008; 154:87–97
56. Calvano SE, Xiao W, Richards DR, et al: A network-based analysis of systemic inflammation in humans. *Nature* 2005; 437:1032–1037
57. Mongardon N, Singer M: Etomidate versus ketamine for sedation in acutely ill patients. *Lancet* 2009; 374:1240; author reply 1241
58. Suliburk J, Helmer K, Moore F, et al: The gut in systemic inflammatory response syndrome and sepsis Enzyme systems fighting multiple organ failure. *Eur Surg Res* 2008; 40:184–189
59. Suliburk JW, Ward JL, Helmer KS, et al: Ketamine-induced hepatoprotection: The role of heme oxygenase-1. *Am J Physiol Gastrointest Liver Physiol* 2009; 296:G1360–G1369
60. Clark MA, Plank LD, Connolly AB, et al: Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis—A randomized, clinical trial. *Crit Care Med* 1998; 26:1650–1659
61. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock NORASEPT II Study Group. *Lancet* 1998; 351:929–933
62. Naveau S, Chollet-Martin S, Dharancy S, et al: A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. *Hepatology* 2004; 39:1390–1397
63. Sharma P, Kumar A, Sharma BC, et al: Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: An open label trial. *J Hepatol* 2009; 50:584–591
64. Meisel C, Scheffold JC, Pschowski R, et al: Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: A double-blind, randomized, placebo-controlled multicenter trial. *Am J Respir Crit Care Med* 2009; 180:640–648
65. Kucukoduk S, Sezer T, Yildiran A, et al: Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks

- with presumed sepsis. *Scand J Infect Dis* 2002; 34:893–897
66. Carr R, Brocklehurst P, Dore CJ, et al: Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): A single-blind, multicentre, randomised controlled trial. *Lancet* 2009; 373:226–233
 67. Holt MP, Cheng L, Ju C: Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. *J Leukoc Biol* 2008; 84:1410–1421
 68. Rosenbloom AJ, Linden PK, Dorrance A, et al: Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. *Chest* 2005; 127:2139–2150
 69. Cabrera J, Inglada L, Quintero E, et al: Large-volume paracentesis and intravenous saline: Effects on the renin-angiotensin system. *Hepatology* 1991; 14:1025–1028
 70. Cabrera J, Falcon L, Gorris E, et al: Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. *Gut* 2001; 48:384–389
 71. Sugrue M, Balogh Z, Malbrain M: Intra-abdominal hypertension and renal failure. *Aust NZ J Surg* 2004; 74:78; discussion 78
 72. Sugrue M, Buhkari Y: Intra-abdominal pressure and abdominal compartment syndrome in acute general surgery. *World J Surg* 2009; 33:1123–1127
 73. Escorsell A, Gines A, Llach J, et al: Increasing intra-abdominal pressure increases pressure, volume, and wall tension in esophageal varices. *Hepatology* 2002; 36: 936–940
 74. Nakatani T, Sakamoto Y, Kaneko I, et al: Effects of intra-abdominal hypertension on hepatic energy metabolism in a rabbit model. *J Trauma* 1998; 44:446–453
 75. Cheatham ML, Safcsak K, Brzezinski SJ, et al: Nitrogen balance, protein loss, and the open abdomen. *Crit Care Med* 2007; 35: 127–131
 76. Joannidis M, Druml W, Forni LG, et al: Prevention of acute kidney injury and protection of renal function in the intensive care unit: Expert opinion of the working group for nephrology, ESICM. *Intensive Care Med* 2009
 77. Brunkhorst FM, Engel C, Bloos F, et al: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 2008; 358:125–139
 78. Dart AB, Mutter TC, Ruth CA, et al: Hydroxyethyl starch (HES) versus other fluid therapies: Effects on kidney function. *Cochrane Database Syst Rev*:CD007594
 79. Veldman BA, Schepkens HL, Vervoort G, et al: Low concentrations of intravenous polygelines promote low-molecular weight proteinuria. *Eur J Clin Invest* 2003; 33: 962–968
 80. Brandt S, Regueira T, Bracht H, et al: Effect of fluid resuscitation on mortality and organ function in experimental sepsis models. *Crit Care* 2009; 13:R186
 81. Groeneveld AJ: Fluids in septic shock: too much of a good thing? *Crit Care* 2010; 14: 101
 82. Finfer S, Bellomo R, Boyce N, et al: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004; 350:2247–2256
 83. Sort P, Navasa M, Arroyo V, et al: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *N Engl J Med* 1999; 341:403–409
 84. Fernandez J, Navasa M, Garcia-Pagan JC, et al: Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. *J Hepatol* 2004; 41:384–390
 85. Arroyo V, Fernandez J, Gines P: Pathogenesis and treatment of hepatorenal syndrome. *Semin Liver Dis* 2008; 28:81–95
 86. Arroyo V, Jimenez W: Complications of cirrhosis II. Renal and circulatory dysfunction Lights and shadows in an important clinical problem. *J Hepatol* 2000; 32:157–170
 87. Vincent JL, Sakr Y, Reinhart K, et al: Is albumin administration in the acutely ill associated with increased mortality? Results of the SOAP study. *Crit Care* 2005; 9:R745–R754
 88. Quinlan GJ, Margaron MP, Mumby S, et al: Administration of albumin to patients with sepsis syndrome: A possible beneficial role in plasma thiol repletion. *Clin Sci (Lond)* 1998; 95:459–465
 89. Meziani F, Kremer H, Tesse A, et al: Human serum albumin improves arterial dysfunction during early resuscitation in mouse endotoxic model via reduced oxidative and nitrosative stresses. *Am J Pathol* 2007; 171: 1753–1761
 90. Hassanein TI, Tofteng F, Brown RS Jr, et al: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. *Hepatology* 2007; 46:1853–1862
 91. Bar-Or D, Thomas GW, Bar-Or R, et al: Commercial human albumin preparations for clinical use are immunosuppressive in vitro. *Crit Care Med* 2006; 34:1707–1712
 92. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008; 36:296–327
 93. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001; 345:1368–1377
 94. Puskarich MA, Marchick MR, Kline JA, et al: One year mortality of patients treated with an emergency department based early goal directed therapy protocol for severe sepsis and septic shock: A before and after study. *Crit Care* 2009; 13:R167
 95. Shoemaker WC, Kram HB, Appel PL, et al: The efficacy of central venous and pulmonary artery catheters and therapy based upon them in reducing mortality and morbidity. *Arch Surg* 1990; 125:1332–1337
 96. Bundgaard-Nielsen M, Ruhnau B, Secher NH, et al: Flow-related techniques for preoperative goal-directed fluid optimization. *Br J Anaesth* 2007; 98:38–44
 97. Giglio MT, Marucci M, Testini M, et al: Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: A meta-analysis of randomized controlled trials. *Br J Anaesth* 2009; 103: 637–646
 98. Pearse R, Dawson D, Fawcett J, et al: Early goal-directed therapy after major surgery reduces complications and duration of hospital stay A randomised, controlled trial [ISRCTN38797445]. *Crit Care* 2005; 9:R687–R693
 99. Nguyen HB, Corbett SW, Steele R, et al: Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. *Crit Care Med* 2007; 35:1105–1112
 100. Hayes MA, Yau EH, Timmins AC, et al: Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption Relationship to outcome. *Chest* 1993; 103:886–895
 101. Pope JV, Jones AE, Gaieski DF, et al: Multicenter study of central venous oxygen saturation (ScvO₂) as a predictor of mortality in patients with sepsis. *Ann Emerg Med* 2009; 55:40–46
 102. Mikkelsen ME, Miltiades AN, Gaieski DF, et al: Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. *Crit Care Med* 2009; 37: 1670–1677
 103. Gattinoni L, Brazzi L, Pelosi P, et al: A trial of goal-oriented hemodynamic therapy in critically ill patients SvO₂ Collaborative Group. *N Engl J Med* 1995; 333:1025–1032
 104. McCarter FD, Nierman SR, James JH, et al: Role of skeletal muscle Na⁺-K⁺ ATPase activity in increased lactate production in sub-acute sepsis. *Life Sci* 2002; 70: 1875–1888
 105. Levy B, Desebbe O, Montemont C, et al: Increased aerobic glycolysis through beta2 stimulation is a common mechanism involved in lactate formation during shock states. *Shock* 2008; 30:417–421
 106. Levy B, Gibot S, Franck P, et al: Relation between muscle Na⁺-K⁺ ATPase activity and raised lactate concentrations in septic shock: A prospective study. *Lancet* 2005; 365:871–875
 107. Crouser ED, Julian MW, Huff JE, et al: Abnormal permeability of inner and outer mitochondrial membranes contributes independently to mitochondrial dysfunction in

- the liver during acute endotoxemia. *Crit Care Med* 2004; 32:478–488
108. Levy RJ, Deutschman CS: Cytochrome c oxidase dysfunction in sepsis. *Crit Care Med* 2007; 35:S468–S475
 109. Porta F, Takala J, Weikert C, et al: Effects of prolonged endotoxemia on liver, skeletal muscle and kidney mitochondrial function. *Crit Care* 2006; 10:R118
 110. Singer M: Mitochondrial function in sepsis: Acute phase versus multiple organ failure. *Crit Care Med* 2007; 35:S441–S448
 111. Protti A, Carre J, Frost MT, et al: Succinate recovers mitochondrial oxygen consumption in septic rat skeletal muscle. *Crit Care Med* 2007; 35:2150–2155
 112. Verma R, Huang Z, Deutschman CS, et al: Caffeine restores myocardial cytochrome oxidase activity and improves cardiac function during sepsis. *Crit Care Med* 2009; 37:1397–1402
 113. Regueira T, Banziger B, Djafarzadeh S, et al: Norepinephrine to increase blood pressure in endotoxaemic pigs is associated with improved hepatic mitochondrial respiration. *Crit Care* 2008; 12:R88
 114. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. *N Engl J Med* 2001; 345:1359–1367
 115. Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006; 354:449–461
 116. Finfer S, Chittock DR, Su SY, et al: Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009; 360:1283–1297
 117. Vanhorebeek I, De Vos R, Mesotten D, et al: Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. *Lancet* 2005; 365:53–59
 118. Chand N, Sanyal AJ: Sepsis-induced cholestasis. *Hepatology* 2007; 45:230–241
 119. Kramer L, Jordan B, Druml W, et al: Incidence and prognosis of early hepatic dysfunction in critically ill patients—A prospective multicenter study. *Crit Care Med* 2007; 35:1099–1104
 120. Takamatsu S, Noguchi N, Kudoh A, et al: Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. *Hepatogastroenterology* 2008; 55:609–614
 121. Shimamatsu K, Wanless IR: Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. *Hepatology* 1997; 26:343–350
 122. Wanless IR, Shiota K: The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: A four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. *Semin Liver Dis* 2004; 24:99–106
 123. Bosch J: Vascular deterioration in cirrhosis: the big picture. *J Clin Gastroenterol* 2007; 41(Suppl 3):S247–S253
 124. Kortgen A, Paxian M, Werth M, et al: Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. *Shock* 2009; 32:358–365
 125. Croner RS, Hoerer E, Kulu Y, et al: Hepatic platelet and leukocyte adherence during endotoxemia. *Crit Care* 2006; 10:R15
 126. Hwang TL, Han ML: The changes of hepatic sinusoidal microcirculation and effects of nitric oxide synthase inhibitor during sepsis. *Hepatogastroenterology* 2003; 50:213–216
 127. Nishida J, McCuskey RS, McDonnell D, et al: Protective role of NO in hepatic microcirculatory dysfunction during endotoxemia. *Am J Physiol* 1994; 267:G1135–G1141
 128. Kortgen A, Silomon M, Pape-Becker C, et al: Thoracic but not lumbar epidural anaesthesia increases liver blood flow after major abdominal surgery. *Eur J Anaesthesiol* 2009; 26:111–116
 129. Troisi R, Praet M, de Hemptinne B: Small-for-size syndrome: what is the problem? *Liver Transpl* 2003; 9:S1
 130. Kelly DM, Zhu X, Shiba H, et al: Adenosine restores the hepatic artery buffer response and improves survival in a porcine model of small-for-size syndrome. *Liver Transpl* 2009; 15:1448–1457
 131. Demetris AJ, Kelly DM, Eghtesad B, et al: Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. *Am J Surg Pathol* 2006; 30:986–993
 132. Maynard N, Bihari D, Beale R, et al: Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. *JAMA* 1993; 270:1203–1210
 133. Rhodes A, Gabe SM, Wendon JA: A prospective study of gastric mucosal ischaemia in paracetamol-induced acute liver failure. *Intensive Care Med* 2000; 26:1268–1271
 134. Gatt M, MacFie J, Anderson AD, et al: Changes in superior mesenteric artery blood flow after oral, enteral, and parenteral feeding in humans. *Crit Care Med* 2009; 37:171–176
 135. Revelly JP, Ayuse T, Brienza N, et al: Dysregulation of the veno-arterial response in the superior mesenteric artery during endotoxic shock. *Crit Care Med* 1995; 23:1519–1527
 136. Moore-Olufemi SD, Padalecki J, Olufemi SE, et al: Intestinal edema: effect of enteral feeding on motility and gene expression. *J Surg Res* 2009; 155:283–292
 137. Cresci G, Cue J: The patient with circulatory shock: To feed or not to feed? *Nutr Clin Pract* 2008; 23:501–509
 138. Besselink MG, van Santvoort HC, Buskens E, et al: Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. *Lancet* 2008; 371:651–659
 139. Besselink MG, van Santvoort HC, Renooij W, et al: Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. *Ann Surg* 2009; 250:712–719
 140. Fukatsu K, Zarzaar BL, Johnson CD, et al: Enteral nutrition prevents remote organ injury and death after a gut ischemic insult. *Ann Surg* 2001; 233:660–668
 141. Fukatsu K, Ueno C, Maeshima Y, et al: Detrimental effects of early nutrition administration after severe gut ischemia-reperfusion. *J Surg Res* 2008; 149:31–38
 142. Grau T, Bonet A, Rubio M, et al: Liver dysfunction associated with artificial nutrition in critically ill patients. *Crit Care* 2007; 11:R10
 143. Grau T, Bonet A: Caloric intake and liver dysfunction in critically ill patients. *Curr Opin Clin Nutr Metab Care* 2009; 12:175–179